Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery

HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC

Cancer control in Latin America

Assessment of cervical and breast cancer screening in Latin America and Caribbean: CanScreen5/CELAC project

ESMO 2022: Highlights, commentary and analysis

Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC

ESMO 2022: Renal roundup

ESMO 2022: Breast cancer highlights

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Optimum treatment strategy algorithm for mCRC